arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ABBOTT LABORATORIES

ABT
$113.55 ▼ -2.02 (-1.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
74 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

ABBOTT LABORATORIES shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $197.9B
Dividend Yield 0.55%
Revenue Growth 7.8% ↗
Op. Margin 12.0% ↘
ROIC 1.2% ↘
FCF / Share $0.53
Trailing P/E 183.2x
Price / Book 3.8x
FCF Yield 0.5%
Debt / Equity 0.57
info Valuation on last close. End-of-day price, Nov 5, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.16B
↑ +7.8% —
Net Income Profit after all expenses
$1.08B
↓ -18.7% —
Operating Margin Operating profit as % of sales
12.0%
↓ -38.7% 72th
FCF / Share Free cash flow per share
$0.53
↓ -2.0% —
Long-Term Debt Long-term obligations
$29.64B
↑ +129.2% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
74
Returns ↓
75
Financial Health ↓
77
Cash Quality ↓
71

Dividend History

Dividend / share · sourced from SEC filings
$2.40 Latest / share
+7.1% YoY
+7.4% 3-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 74 quarters